Founded Year

2011

Stage

Series A - III | Alive

Total Raised

$11.42M

Last Raised

$3.71M | 5 yrs ago

About TargEDys

TargEDys is dedicated to the modulation of appetite and develops functional food, medical food and pharmaceutical products to harness the microbiome's ability to regulate appetite and thus maintain or restore weight and metabolic health. The Company's products target high appetite leading to overweight, and low appetite leading to malnourishment in elderly people, cachexia and anorexia.

TargEDys Headquarter Location

75 Impasse de Lyons

Rouen, 76000,

France

+33 6 79 39 41 16

TargEDys's Product Videos

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

TargEDys's Products & Differentiation

See TargEDys's products and how their products differentiate from alternatives and competitors

  • EnteroSatys

    EnteroSatys is a precision probiotic supplement in gastroresistant capsules based on the unique strain Hafnia alvei HA4597 which produces the protein ClpB, a conformational mimetic of the satiety hormone alpha-MSH. Able to activate the receptor of alpha-MSH, ClpB stimulates feeling of fullness, reduces food intake and supports weight loss.

    Differentiation

    EnteroSatys has an efficacy, shown in a human clinical trial with 230 overweight adults, that almost compares to that of pharmaceutical products for weight management, with the safety and tolerance … 

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Expert Collections containing TargEDys

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

TargEDys is included in 2 Expert Collections, including Omics.

O

Omics

275 items

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

TargEDys Patents

TargEDys has filed 9 patents.

The 3 most popular patent topics include:

  • Nutrition
  • Acid fast bacilli
  • Nontuberculous mycobacteria
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/5/2017

1/12/2021

Nontuberculous mycobacteria, Acid fast bacilli, Nutrition, G protein coupled receptors, Food additives

Grant

Application Date

4/5/2017

Grant Date

1/12/2021

Title

Related Topics

Nontuberculous mycobacteria, Acid fast bacilli, Nutrition, G protein coupled receptors, Food additives

Status

Grant

Latest TargEDys News

New Double-Blind Randomized Placebo-Controlled Trial Confirms Hafnia alvei HA4597® helps improve weight loss in overweight adults

Jun 15, 2021

New Double-Blind Randomized Placebo-Controlled Trial Confirms Hafnia alvei HA4597® helps improve weight loss in overweight adults A collaboration between TargEDys, the French Institute of Research Inserm, Rouen Normandy University and Hospital, and Analyze-Realize in Berlin led to the publication of the first ever human trial on the efficacy of the novel probiotic Hafnia alvei HA4597® in the management of overweight (1). A growing body of evidence points to the existence of a microbial component in the epidemic of obesity and overweight since the first evidence of a difference between the microbiota of obese and lean people, and its transmissibility back in 2006 (2). The investigation behind the mechanism of action explaining the results of this new study also dates back many years, since the research on anti-alpha-MSH antibodies and the discovery of Caseinolytic peptidase B (ClpB). ClpB, thanks to its conformation and analogous sequence to the satiety hormone alpha-MSH, is a functional mimetic of this satiety hormone (3, 4) and is negatively associated with body weight and Body Mass Index (5, 6). Two recent publications showed Hafnia alvei HA4597®, a bacterium from French cheese camembert producing ClpB, was able to reduce food intake and weight gain in different murine models of obesity (5, 7). The present study, the first with Hafnia alvei in humans, is conducted according to pharmaceutical standards in 236 overweight men and women following a 20% caloric restriction, who were supplemented for 12 weeks with 2 capsules per day of either HA4597® (100 billion cells) or a placebo. Results: The primary endpoint, percentage of subjects losing at least 3% body weight after 12 weeks, was significantly higher in HA4597® group than placebo (57.7% vs. 41.7%, p=0.028, thus 38% better response in the probiotic group, per protocol results). 51% more subjects also met the 4% body weight loss threshold in the probiotic group (46.2 vs 30.6%, p=0,.024). The participants in the probiotic group saw a significant increase in the feeling of fullness (p=0.009 vs both baseline and placebo), saw a further 1.2 cm reduction in hip circumference, as well as a significant decrease in blood glucose (p=0.027) and cholesterol (unpublished). The participants also reported increased feeling of fullness when supplemented with HA4597®, reflecting the mechanism of action through the induction of satiety pathways. The researchers conclude that “supplementation with HA4597® represents an innovative and well-tolerated strategy to enhance the efficacy of dietary advice for the control of excess body weight; the “precision probiotic” HA4597® (8) paves the way to the precision medicine and nutrition by identifying responders thanks to a gut microbial-based personalized approach.” Grégory Lambert, CEO of TargEDys, declares: “This will be a game-changer in the sector of weight management, with finally a solution that meets consumers expectations in terms of safety and naturality, while also bringing a real, demonstrated efficacy based on molecular mimicry and the biochemical regulation of appetite.” References: Déchelotte, P. et al. The Probiotic Strain  alveiHA4597® Improves Weight Loss in Overweight Subjects under Moderate Hypocaloric Diet: A Proof-of-Concept, Multicenter Randomized, Double-Blind Placebo-Controlled Study. Nutrients 2021, 13, 1902. https://doi.org/10.3390/nu13061902 Turnbaugh, P., Ley, R., Mahowald, M. et al.An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031 (2006). https://doi.org/10.1038/nature05414 Fetissov SO et al. Bacterial Protein Mimetic of Peptide Hormone as a New Class of Protein- based Drugs. Curr Med Chem. 2019;26(3):546-553. doi: 10.2174/0929867324666171005110620. Tennoune N et al. Bacterial ClpB heat-shock protein, an antigen-mimetic of the anorexigenic peptide α-MSH, at the origin of eating disorders. Transl Psychiatry. 2014 Oct 7;4(10):e458. doi: 10.1038/tp.2014.98. Legrand R, et al. Commensal Hafnia alvei strain reduces food intake and fat mass in obese mice-a new potential probiotic for appetite and body weight management. Int J Obes (Lond). 2020 May;44(5):1041-1051. doi: 10.1038/s41366-019-0515-9. Arnoriaga-Rodríguez M, et al. Gut bacterial ClpB-like gene function is associated with decreased body weight and a characteristic microbiota profile. 2020 Apr 30;8(1):59. doi: 10.1186/s40168-020-00837-6. Lucas N. et al. Hafnia alveiHA4597 Strain Reduces Food Intake and Body Weight Gain and Improves Body Composition, Glucose, and Lipid Metabolism in a Mouse Model of Hyperphagic Obesity. Microorganisms. 2019 Dec 23;8(1):35. doi: 10.3390/microorganisms8010035. Veiga, Pet al. Moving from Probiotics to Precision Probiotics. Microbiol.2020, 5, 878–880. Microbiome-based Diagnostics & Biomarkers: Free Market Report Sign Up to Free Newsletter The Microbiome Drug Database

TargEDys Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

TargEDys Rank

You May Also Like

A
A-Mansia Biotech

A-Mansia Biotech is a Belgian-based microbiome start-up based on discoveries made by its founding scientists, Professor Willem M. de Vos, from Wageningen University, The Netherlands and Professor Patrice D. Cani, from the University of Louvain, Belgium. Its R&D will be conducted in collaboration with the laboratories of University of Louvain and Wageningen University, and contract organizations. A-Mansia is developing health products based on the unique properties of the Akkermansia muciniphila bacteria.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.